Headlines about Akari Therapeutics (NASDAQ:AKTX) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akari Therapeutics earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.1089779908658 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several research analysts have weighed in on AKTX shares. Zacks Investment Research downgraded Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 26th. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $7.50.

Akari Therapeutics (NASDAQ:AKTX) traded down $0.03 during trading on Wednesday, hitting $3.46. The company had a trading volume of 166,300 shares, compared to its average volume of 192,707. Akari Therapeutics has a 12-month low of $3.18 and a 12-month high of $22.20. The stock has a market capitalization of $41.10, a P/E ratio of -12.36 and a beta of -9.07.

Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.91. research analysts predict that Akari Therapeutics will post -2 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Akari Therapeutics (AKTX) Given News Impact Score of 0.21” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/24/akari-therapeutics-aktx-given-news-impact-score-of-0-21.html.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Insider Buying and Selling by Quarter for Akari Therapeutics (NASDAQ:AKTX)

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.